Pharmacologic reperfusion strategies for the treatment of ST-segment elevation myocardial infarction

Reviews in Cardiovascular Medicine

Volumn 4, Issue 4, 2003, Pages 216-227

  Young, John J ^a   Kereiakes, Dean J ^a  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

Elevation myocardial infarction; Fibrinolytic therapy; GP IIb IIIa receptor inhibition; Infarct related artery patency; Low molecular weight heparin; Myocardial reperfusion; Percutaneous coronary intervention; St segment

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; CLOPIDOGREL; ENOXAPARIN; HEPARIN; LANOTEPLASE; METOPROLOL; RETEPLASE; STREPTOKINASE; TENECTEPLASE;

ARTERY CATHETERIZATION; BLEEDING TENDENCY; BRAIN HEMORRHAGE; CLINICAL TRIAL; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; DRUG HALF LIFE; DRUG MECHANISM; HEART CONDUCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REPERFUSION; HEART REINFARCTION; HUMAN; MORTALITY; REVIEW; ST SEGMENT ELEVATION; STROKE; SYMPTOMATOLOGY; TREATMENT OUTCOME; VASCULAR PATENCY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 0348038733     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343:311-322.
2. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Committee on Management of Acute Myocardial Infarction. Circulation. 1999;100:1016-1030.
3. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA. 1997;278:2093-2098.
4. Every NR, Parsons LS, Hlatky M, et al; for the Myocardial Infarction Triage and Intervention Investigators. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. N Engl J Med. 1996;335:1253-1260.
5. Tiefenbrunn AJ, Chandra NC, French WJ, et al. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol. 1998;31:1240-1245.
6. Magid DJ, Calonge BN, Rumsfeld JS, et al. Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic therapy. JAMA. 2000;284:3131-3138.
7. Canto JG, Every NR, Magid DJ, et al.The volume of primary angioplasty procedures and survival after acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators. N Engl J Med. 2000;342:1573-1580.
8. Brodie BR, Stone GW, Morice MC, et al; for the Stent Primary Angioplasty in Myocardial Infarction Study Group. Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial). Am J Cardiol. 2001;88:1085-1090.
9. Rogers WJ, Bowlby LJ, Chandra NC, et al. Treatment of myocardial infarction in the United States (1990 to 1993): observations from the National Registry of Myocardial Infarction. Circulation. 1994;90:2103-2114.
10. French WJ. Trends in acute myocardial infarction management: use of the National Registry of Myocardial Infarction in quality improvement. Am J Cardiol. 2000;85(5A):5B-9B.
11. Eagle KA, Goodman SG, Avezum A, et al. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet. 2002;359:373-377.
12. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999. J Am Coll Cardiol. 2000;36:2056-2063.
13. Callahan KP, Malinin AI, Gurbel PA, et al. Platelets and thrombolysis: cooperation or contrariety? Heart Drug. 2001;1:281-290.
14. Hiatt MD. Thrombolytic therapy with streptokinase and tissue plasminogen activator in a patient with suspected acute myocardial infarction: a decision analysis. Cardiology. 1999;91:243-249.
15. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;22:397-402.
16. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
17. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I findings. N Engl J Med. 1985;312:932-936.
18. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
19. Simes RJ, Topol EJ, Holmes DR Jr, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete infarct artery reperfusion. GUSTO-1 Investigators. Circulation. 1995;91:1923-1928.
20. Weitz JI, Leslie B, Ginsberg JG. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced need fibrinogen proteolysis. J Clin Invest. 1991;87:1082-1090.
21. Stewart RJ, Fredenburgh JC, Weitz JI. Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E. J Biol Chem. 1998; 273:18292-18299.
22. Owen J, Friedman KD, Grossman BA, et al. Quantitation of fragment X formation during thrombolytic therapy with streptokinase or tissue plasminogen activator. J Clin Invest. 1987;79:1642-1647.
23. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118-1123.
24. The InTIME-II Investigators. Intravenous NPA for the treatment of infracting myocardium early: InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J. 2000;21:2005-2013.
25. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354:716-722.
26. Lincoff AM, Topol EJ. Illusion of reperfusion: does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation. 1993;88:1361-1374.
27. Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation. 1996;93:1993-1999.
28. Porter TR, Li S, Oster R, et al. The clinical implications of no reflow demonstrated with intravenous perfluorocarbon containing microbubbles following restoration of Thrombolysis In Myocardial Infarction (TIMI) 3 flow in patients with acute myocardial infarction. Am J Cardiol. 1998;82:1173-1177.
29. Gibson CM, Murphy SA, Marble SJ, et al. Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? TIMI Study Group. Am J Cardiol. 2001;87:450-453, A6.
30. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000;101:125-130.
31. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 2002;105:1909-1913.
32. Stone GW, Peterson MA, Lansky AJ, et al. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol. 2002; 39:591-597.
33. Cannon CP. Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction. J Am Coll Cardiol. 1999;34:1395-1402.
34. Cohen M. Treatment of unstable angina: the role of platelet inhibitors and anticoagulants J Invasive Cardiol. 1999;11:147-159.
35. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation. 1998;98:734-741.
36. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000;35:915-921.
37. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-1903.
38. Schomig A, Kastrati A, Dirschinger J, et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction: Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med. 2000;343:385-391.
39. van den Merkhof LF, Zijlstra F, Olsson H, et al. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty: results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J Am Coll Cardiol. 1999;33:1528-1532.
40. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation. 2000;101:2788-2794.
41. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation. 1999;99:2720-2732.
42. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1997;336:1621-1628.
43. Topol EJ, the GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001; 357:1905-1914.
44. Lincoff AM, Califf RM, Van de Werf F, et al. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA. 2002;288:2130-2135.
45. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358:605-613.
46. Kereiakes DJ, Montalescot G, Antman EM, et al. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus. Am Heart J. 2002;144:615-624.
47. Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 trial. Circulation. 2002;105:1642-1649.
48. Yusuf S, Zhao F, Mehta SR, et al; for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
49. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
50. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
51. Second Chinese Cardiac Study (CSS-2) Collaborative Group. Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. J Cardiovasc Risk. 2000;6:435-441.
52. The TIMI Study Group Web site. Clopidogrel as Adjunctive Reperfusion Therapy - The Clopidogrel as Adjunctive Reperfusion Therapy- Thrombolysis in Myocardial Infarction (CLARITY-TIMI)- 28 Trial. Available at: www.timi.org/files/slides/designsofongoingtrials2002.ppt. Accessed January 2003.
53. Verma S, Fedak PW, Weisel RD, et al. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation. 2002; 105:2332-2336.
54. Rafii S, Meeus S, Dias S, et al. Contribution of marrow-derived progenitors to vascular and cardiac regeneration. Semin Cell Dev Biol. 2002;13:61-67.
55. Strauef BE, Brehm M, Zeus T, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002; 106:1913-1918.
56. Humma LM, Terra SG. Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management. Am J Health Syst Pharm. 2002; 59:1241-1252.
57. Califf RM, Faxon DP. The need for centers to care for patients with acute coronary syndromes. Circulation. In press.
58. Topol EJ, Kereiakes DJ. Regionalization of care for acute ischemic heart disease: a call for specialized centers. Circulation. In press.